X

Trial Profile

A Randomized Phase 2a, Multicenter, Open-label Study Evaluating ABI-H0731-Containing Regimens in Patients With Chronic Hepatitis B

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entecavir (Primary) ; Peginterferon alfa (Primary) ; Vebicorvir (Primary)
Indications Hepatitis B
Focus Adverse reactions
Sponsors Assembly Biosciences

Most Recent Events

04 Oct 2023 Status changed to discontinued.
24 Jun 2023 Results assessing the relative safety and efficacy of vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection, presented at the European Association for the Study of the Liver Congress 2023.
21 Jun 2023 Results presented in an Assembly Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com